NasdaqGS:ARWRBiotechs
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After New Plozasiran Phase 2 Extension Data
Arrowhead Pharmaceuticals (ARWR) shares are in focus after the company released two-year open-label extension data for plozasiran, showing large and durable triglyceride reductions with a consistent safety profile in patients with hypertriglyceridemia.
See our latest analysis for Arrowhead Pharmaceuticals.
The new plozasiran data arrived after a mixed stretch for Arrowhead's share price, with a 7 day share price return of 5.62% offsetting recent declines. Over the past year, the total...